Jean-Paul CONCORDET
Chargé de recherche
Entité de rattachement
Équipe GE2R
Contact
Courriel
jean-paul.concordet [at] mnhn.fr
Téléphone
01 40 79 37 09
Adresse(s)
CNRS UMR 7196 / INSERM U1154
43, rue Cuvier - Case Postale 26
75231 Paris Cedex 05, France
Responsabilités dans l'unité
Directeur adjoint
Publications
2022
- , novembre 2022 — Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression. Nature Communications vol. 13, n° 1, p. 6618
- , juin 2022 — Disease modeling by efficient genome editing using a near PAM-less base editor in vivo. Nature Communications vol. 13, n° 1, dir. {Nature Publishing Group} p. 3435
- , 2022 — CRISPR gene editing in pluripotent stem cells reveals the function of MBNL proteins during human in vitro myogenesis. Human Molecular Genetics vol. 31, n° 1, dir. {Oxford University Press (OUP)} p. 41-56
2021
- , décembre 2021 — « Tagging Proteins with Fluorescent Reporters Using the CRISPR/Cas9 System and Double-Stranded DNA Donors » in Multiprotein Complexes.. , , p. 39-57
- , octobre 2021 — Recent Progress in Genome Editing for Gene Therapy Applications: The French Perspective. Human Gene Therapy vol. 32, 19-20, dir. {Mary Ann Liebert} p. 1059-1075
- , mars 2021 — Correction of \beta-thalassemia by CRISPR/Cas9 editing of the \alpha-globin locus in human hematopoietic stem cells. Blood Advances vol. 5, n° 5, dir. {The American Society of Hematology} p. 1137-1153
- , février 2021 — Precise base editing for the in vivo study of developmental signaling and human pathologies in zebrafish. eLife vol. 10, , dir. {eLife Sciences Publication}
- , 2021 — Gene Tagging with the CRISPR-Cas9 System to Facilitate Macromolecular Complex Purification. Methods in molecular biology (Clifton, N.J.) vol. 2305, , p. 153-174
2020
- , juillet 2020 — Characterization of post-edited cells modified in the TFAM gene by CRISPR/Cas9 technology in the bovine model. PLoS ONE vol. 15, n° 7, dir. {Public Library of Science} e0235856
- , juillet 2020 — Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins. Nature Communications vol. 11, n° 1, dir. {Nature Publishing Group} p. 3778